NZ582441A - Immunogenic composition for use in vaccination against staphylococcei - Google Patents

Immunogenic composition for use in vaccination against staphylococcei

Info

Publication number
NZ582441A
NZ582441A NZ582441A NZ58244105A NZ582441A NZ 582441 A NZ582441 A NZ 582441A NZ 582441 A NZ582441 A NZ 582441A NZ 58244105 A NZ58244105 A NZ 58244105A NZ 582441 A NZ582441 A NZ 582441A
Authority
NZ
New Zealand
Prior art keywords
protein
immunogenic composition
staphylococcal
group
immunogenic
Prior art date
Application number
NZ582441A
Other languages
English (en)
Inventor
Cindy Castado
Nicolas Pierre Fernand Lecrenier
Cecile Anne Neyt
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36000843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ582441(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0421082A external-priority patent/GB0421082D0/en
Priority claimed from GB0421078A external-priority patent/GB0421078D0/en
Priority claimed from GB0421079A external-priority patent/GB0421079D0/en
Priority claimed from GB0421081A external-priority patent/GB0421081D0/en
Priority claimed from GB0503143A external-priority patent/GB0503143D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Priority to NZ593693A priority Critical patent/NZ593693A/xx
Publication of NZ582441A publication Critical patent/NZ582441A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ582441A 2004-09-22 2005-09-20 Immunogenic composition for use in vaccination against staphylococcei NZ582441A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ593693A NZ593693A (en) 2004-09-22 2005-09-20 Immunogenic composition comprising staphylococcal proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0421082A GB0421082D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421078A GB0421078D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421079A GB0421079D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421081A GB0421081D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0503143A GB0503143D0 (en) 2005-02-15 2005-02-15 Immunogenic composition
NZ553775A NZ553775A (en) 2004-09-22 2005-09-20 Immunogenic composition for use in vaccination against staphylococcei

Publications (1)

Publication Number Publication Date
NZ582441A true NZ582441A (en) 2011-09-30

Family

ID=36000843

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ582441A NZ582441A (en) 2004-09-22 2005-09-20 Immunogenic composition for use in vaccination against staphylococcei
NZ553775A NZ553775A (en) 2004-09-22 2005-09-20 Immunogenic composition for use in vaccination against staphylococcei
NZ593693A NZ593693A (en) 2004-09-22 2005-09-20 Immunogenic composition comprising staphylococcal proteins
NZ553776A NZ553776A (en) 2004-09-22 2005-09-20 Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ553775A NZ553775A (en) 2004-09-22 2005-09-20 Immunogenic composition for use in vaccination against staphylococcei
NZ593693A NZ593693A (en) 2004-09-22 2005-09-20 Immunogenic composition comprising staphylococcal proteins
NZ553776A NZ553776A (en) 2004-09-22 2005-09-20 Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.

Country Status (17)

Country Link
US (6) US20080085289A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (9) EP2181714A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP2008513409A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (4) KR20070058631A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN101128215B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2005287505A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BRPI0515516B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (4) CA2580103C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (4) ES2540771T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (4) IL181825A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (2) MA28994B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX2007003402A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO20071609L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (4) NZ582441A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2402347C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (3) WO2006032500A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200702224B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
US20080085289A1 (en) * 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
CN101175508A (zh) 2004-10-21 2008-05-07 惠氏公司 表皮葡萄球菌多肽抗原的免疫原性组合物
AU2005310981A1 (en) * 2004-10-25 2006-06-08 The University Of Western Ontario Vaccines, compositions and methods based on Staphylococcus aureus iron-regulated surface determinants IsdA, IsdB, and IsdC
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
WO2007000342A2 (en) * 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
EP1998800A2 (en) * 2006-01-18 2008-12-10 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
CN103169960A (zh) * 2006-03-30 2013-06-26 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
US8206923B2 (en) * 2006-04-24 2012-06-26 Elvira Garza Gonzalez Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
TW200744632A (en) * 2006-06-12 2007-12-16 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EP2374467B1 (en) * 2007-05-04 2013-08-28 Martin Krönke Protective staphylococcus aureus vaccine based on cell wall-associated proteins
US8146781B2 (en) * 2007-08-09 2012-04-03 Huhtamaki, Inc. Dispenser for viscous condiments
WO2009023164A2 (en) * 2007-08-10 2009-02-19 President And Fellows Of Harvard College Induction of mucosal immunity
KR101661946B1 (ko) * 2007-08-31 2016-10-05 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
HUE027249T2 (en) 2008-03-03 2016-10-28 Novartis Ag TLR activity modulator compounds and preparations
CN101981452B (zh) * 2008-03-31 2017-05-17 大塚制药株式会社 肺炎球菌检测方法
KR20110009158A (ko) * 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
TWI551295B (zh) * 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CA2738793A1 (en) * 2008-09-30 2010-04-08 University Of Maryland, Baltimore Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
EP2414387B1 (en) 2009-04-03 2015-12-16 University Of Chicago Compositions and methods related to protein a (spa) variants
ES2658863T3 (es) 2009-06-10 2018-03-12 Glaxosmithkline Biologicals Sa Vacunas que contienen benzonaftiridina
TWI505834B (zh) * 2009-06-22 2015-11-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
SI2445522T1 (sl) * 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
WO2012122533A2 (en) * 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
SMT201700275T1 (it) 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP6091214B2 (ja) * 2009-11-16 2017-03-08 ザ ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレイティド ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CA2784144C (en) 2009-12-17 2017-07-11 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
CA2797040C (en) 2010-04-23 2014-07-08 Serum Institute Of India, Ltd. Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
CN102268444B (zh) * 2010-06-03 2015-05-13 中国人民解放军军事医学科学院生物工程研究所 金黄色葡萄球菌截短SasA蛋白在大肠杆菌中的表达及应用
EP2588120B1 (en) 2010-07-02 2017-11-15 The University of Chicago Compositions and methods related to protein a (spa) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US20130115209A1 (en) * 2010-07-15 2013-05-09 Tessie B. McNeely Protective vaccine based on staphylococcus aureus protein sa2412
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
EP2638058B1 (en) * 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
WO2012085872A2 (en) 2010-12-22 2012-06-28 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens
KR101993839B1 (ko) * 2011-02-08 2019-06-28 메디뮨 엘엘씨 스타필로코커스 아우레우스 알파 독소에 특이적으로 결합하는 항체 및 이의 사용 방법
CA2825770A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2012177658A2 (en) * 2011-06-19 2012-12-27 New York Univeristy Methods of treating and preventing staphylococcus aureus infections and associated conditions
WO2012177660A2 (en) 2011-06-19 2012-12-27 New York University Leukotoxin e/d as a new anti-inflammatory agent and microbicide
WO2013025834A2 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
WO2013066731A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2451 protein
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
JP6251730B2 (ja) 2012-04-26 2017-12-20 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
US9968668B2 (en) 2012-04-26 2018-05-15 The University Of Chicago Staphylococcal coagulase antigens and methods of their use
HK1212208A1 (en) * 2012-05-09 2016-06-10 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin
WO2013184900A2 (en) * 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
US9376487B2 (en) 2012-07-10 2016-06-28 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2493 protein
CN102993308B (zh) * 2012-09-29 2014-11-05 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原hi2及制备方法和应用
CN102898511B (zh) * 2012-10-19 2014-05-07 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌重组基因工程疫苗候选抗原i12c制备中的纯化方法
CN103087198B (zh) * 2013-01-21 2014-03-12 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原i1c及制备方法和应用
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CN103333254A (zh) * 2013-06-21 2013-10-02 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）重组蛋白疫苗i1c的纯化方法
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
CN105483138B (zh) * 2016-01-22 2019-03-26 吉林大学 一种与致病力相关的灰霉病菌基因BcAtm1及其应用
WO2017137954A2 (en) * 2016-02-12 2017-08-17 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
CN109922828A (zh) * 2016-10-20 2019-06-21 Km生物医药股份公司 使用具有降低了的分子量的PRP的Hib结合疫苗的制造方法
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
FI3752182T3 (fi) 2018-02-12 2024-07-30 Inimmune Corp Tollin kaltaisen reseptorin ligandeja
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
CN109395072B (zh) * 2018-10-30 2021-11-30 中国兽医药品监察所 一种腐败梭菌α毒素基因工程疫苗及其生产方法
CN110055276A (zh) * 2019-01-28 2019-07-26 杨凌职业技术学院 一种金葡菌靶向抗菌肽细菌诱导型表达载体及其重组细胞
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
CN110892989B (zh) * 2019-06-27 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解便秘功能的副干酪乳杆菌et-22
CN112391304B (zh) * 2019-08-15 2023-04-07 上海交通大学 副血链球菌f278及其用途
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN110590910A (zh) * 2019-09-27 2019-12-20 黑龙江八一农垦大学 能够增强细胞免疫应答和抗感染作用的合成肽
CN111072775B (zh) * 2019-12-26 2021-08-20 成都欧林生物科技股份有限公司 抗MntC蛋白抗体及其应用和包含其的试剂盒
CN111138551A (zh) * 2020-01-15 2020-05-12 黑龙江八一农垦大学 一种预防金黄色葡萄球菌和白色念珠菌感染的atm融合蛋白的制备及应用
JP2023512215A (ja) * 2020-01-29 2023-03-24 ザ ジャクソン ラボラトリー 細菌混和物
KR20230117105A (ko) 2020-11-04 2023-08-07 엘리고 바이오사이언스 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB116556A (en) 1917-06-21 1918-06-20 British Thomson Houston Co Ltd Improvements in and relating to Dynamo Electric Machines.
SE335780B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1964-09-14 1971-06-07 Canadian Patents Dev
FR2227861B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1973-05-04 1976-07-02 Anvar
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5320951A (en) 1987-06-01 1994-06-14 Hoeoek Magnus Fibronectin binding protein as well as its preparation
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
EP0845537A1 (en) 1989-08-18 1998-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
ATE162219T1 (de) 1989-11-16 1998-01-15 Univ Duke Transformation von tierischen hautzellen mit hilfe von partikeln
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
DK0648127T3 (da) * 1991-11-22 2003-05-19 Univax Biolog Inc Type I- og type II-overfladeantigener associeret med Staphylococcus epidermidis
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
HU219808B (hu) 1992-06-25 2001-08-28 Smithkline Beecham Biologicals S.A. Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
MX9400940A (es) 1993-02-05 1994-08-31 Smithkline Beecham Plc Peptido d1-d4 aislado de staphylococcus aureus, anticuerpos monoclonales, procedimientos para su preparacion y composiciones farmaceuticas que los incluyen.
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
BR9405957A (pt) 1993-03-23 1995-12-12 Smithkline Beecham Biolog Composições de vacina contendo lipidio A deacilatado 3-0 monofosforil
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69433341T2 (de) 1993-09-22 2004-04-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
BR9505691A (pt) 1994-01-21 1996-01-16 Agracetus Instrumento para transporte de gente acionado por gás
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9521146D0 (en) 1995-10-16 1995-12-20 Smithkline Beecham Plc Novel compounds
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
RU2122862C1 (ru) * 1995-12-08 1998-12-10 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
DE69734601T2 (de) 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
CA2253549C (en) 1996-06-18 2005-10-25 Alza Corporation Device for enhancing transdermal agent delivery or sampling
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU722574B2 (en) 1996-12-20 2000-08-10 Alza Corporation Device and method for enhancing transdermal agent flux
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
CA2310217A1 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
NZ504894A (en) 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9806762D0 (en) * 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
AU761021B2 (en) 1998-07-10 2003-05-29 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
CA2333931C (en) * 1998-07-15 2013-09-03 Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AU762978B2 (en) 1998-08-31 2003-07-10 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
KR100644953B1 (ko) * 1998-08-31 2006-11-10 인히비텍스, 인코포레이티드 다성분 백신
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
MXPA01002120A (es) 1998-08-31 2003-03-27 Trinity College Dublin Polipeptidos y polinucleotidos de estafilococo negativo a coagulasa.
US6355625B1 (en) 1998-09-14 2002-03-12 Nabi Compositions of β-glucans and specific IGIV
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU1478301A (en) 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
WO2002045742A2 (en) * 2000-09-12 2002-06-13 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002074324A1 (en) 2001-03-15 2002-09-26 The Texas A & M University System Collagen-binding adhesin from staphylococcus epidermidis and method of use
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CA2450939C (en) 2001-06-15 2012-11-06 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
JP4404627B2 (ja) 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US7157443B2 (en) 2001-12-11 2007-01-02 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
JP2005536185A (ja) 2002-03-05 2005-12-02 インヒビテックス インコーポレーテッド コアグラーゼ陰性ブドウ球菌タンパク質を認識するモノクローナルおよびポリクローナル抗体
WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
MXPA05005045A (es) * 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
US9296795B2 (en) * 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20080085289A1 (en) 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
KR20110009158A (ko) * 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
WO2012085872A2 (en) 2010-12-22 2012-06-28 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens

Also Published As

Publication number Publication date
JP6594385B2 (ja) 2019-10-23
EP2305296A1 (en) 2011-04-06
AU2005287532A1 (en) 2006-03-30
KR20070054732A (ko) 2007-05-29
AU2005287502B2 (en) 2011-12-01
CA2584290A1 (en) 2006-03-30
NZ593693A (en) 2013-08-30
JP2015166365A (ja) 2015-09-24
EP2893938B1 (en) 2019-03-06
ES2472441T3 (es) 2014-07-01
CN102657855B (zh) 2015-12-09
KR101508563B1 (ko) 2015-04-07
NO20071609L (no) 2007-06-18
EP2305294A1 (en) 2011-04-06
BRPI0515520A (pt) 2008-07-29
EP2298340B1 (en) 2014-04-16
IL182639A0 (en) 2011-08-01
IL223141A0 (en) 2012-12-31
JP2008513406A (ja) 2008-05-01
RU2007110029A (ru) 2008-10-27
IL181920A (en) 2014-12-31
WO2006032500A2 (en) 2006-03-30
AU2005287502A1 (en) 2006-03-30
EP2181714A3 (en) 2010-06-23
IL223141B (en) 2018-06-28
IL181920A0 (en) 2011-07-31
NO20071610L (no) 2007-06-20
JP2012107028A (ja) 2012-06-07
MA28995B1 (fr) 2007-11-01
WO2006032500A3 (en) 2006-06-22
KR20120128724A (ko) 2012-11-27
US20150328302A1 (en) 2015-11-19
US20080095777A1 (en) 2008-04-24
WO2006032475A3 (en) 2007-01-25
US20200179504A1 (en) 2020-06-11
EP2305295B1 (en) 2015-04-01
NZ553776A (en) 2010-05-28
ES2730275T3 (es) 2019-11-11
BRPI0515516A (pt) 2008-07-29
EP2893938A1 (en) 2015-07-15
KR20070058631A (ko) 2007-06-08
EP2305295A1 (en) 2011-04-06
ZA200702224B (en) 2016-09-28
ES2540771T3 (es) 2015-07-13
US10548963B2 (en) 2020-02-04
CA2580103C (en) 2021-11-16
US20110008385A1 (en) 2011-01-13
HK1155658A1 (en) 2012-05-25
KR101359930B1 (ko) 2014-02-12
CA2983954C (en) 2019-09-17
RU2402347C2 (ru) 2010-10-27
EP1793849A2 (en) 2007-06-13
ES2540770T3 (es) 2015-07-13
EP2181714A2 (en) 2010-05-05
AU2005287532B2 (en) 2011-09-01
IL181825A0 (en) 2007-07-04
EP1791559A2 (en) 2007-06-06
CN101128215B (zh) 2012-10-10
KR101505496B1 (ko) 2015-03-25
CA2983954A1 (en) 2006-03-30
BR122016029840B1 (pt) 2021-10-13
JP2008513409A (ja) 2008-05-01
MA28994B1 (fr) 2007-11-01
US20080085289A1 (en) 2008-04-10
BRPI0515516B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-05-25
WO2006032475A2 (en) 2006-03-30
BRPI0515516B1 (pt) 2017-08-08
JP2018048132A (ja) 2018-03-29
KR20130087633A (ko) 2013-08-06
EP2305294B1 (en) 2015-04-01
AU2005287505A1 (en) 2006-03-30
CA2580137A1 (en) 2006-03-30
EP1804833A2 (en) 2007-07-11
WO2006032472A2 (en) 2006-03-30
JP5775005B2 (ja) 2015-09-09
NZ553775A (en) 2010-05-28
WO2006032472A3 (en) 2006-07-20
CN102657855A (zh) 2012-09-12
MX2007003400A (es) 2008-03-04
MX2007003402A (es) 2007-05-10
US20190076516A1 (en) 2019-03-14
EP2298340A1 (en) 2011-03-23
CA2580103A1 (en) 2006-03-30
CN101128215A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
US10548963B2 (en) Immunogenic composition for use in vaccination against staphylococci
RU2521501C2 (ru) Иммуногенная композиция для применения в вакцинации против стафилококков
AU2011203550B2 (en) Immunogenic composition
AU2011265368B2 (en) Immunogenic composition
HK1139869A (en) Immunogenic composition for use in vaccination against staphylococcei
HK1155658B (en) Immunogenic composition for use in vaccination against staphylococcei
AU2013200670A1 (en) Immunogenic composition

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2016 BY THOMSON REUTERS

Effective date: 20150827

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2017 BY THOMSON REUTERS

Effective date: 20160816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2018 BY THOMSON REUTERS

Effective date: 20170819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2019 BY THOMSON REUTERS

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2020 BY THOMSON REUTERS

Effective date: 20190817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2021 BY THOMSON REUTERS

Effective date: 20200820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2022 BY ANAQUA SERVICES

Effective date: 20210819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2023 BY ANAQUA SERVICES

Effective date: 20220819

LAPS Patent lapsed